Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data
- PMID: 31339579
- DOI: 10.1002/hon.2645
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
